VARC Consensus Report: The FDA Perspective  by Hillebrenner, Matthew G. et al.
T
b
U
C
t
o
e
t
t
c
m
p
h
u
o
r
p
w
g
i
t
D
C
c
d
t
m
C
i
(
v
t
m
o
A
a
F
U
b
r
a
H
e
Journal of the American College of Cardiology Vol. 57, No. 3, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PCurrent Opinion
VARC Consensus Report: The FDA Perspective
Matthew G. Hillebrenner, Julie A. Swain, Bram Zuckerman
Silver Spring, Maryland
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.12.004a
c
a
g
r
t
r
i
r
r
i
t
r
b
e
a
A
r
F
e
d
b
a
i
l
f
i
i
t
c
t
s
w
e
c
u
i
t
m
i
ihe Food and Drug Administration (FDA) is responsi-
le for protecting and promoting the public health of
.S. citizens. In keeping with this mission, FDA’s
enter for Devices and Radiological Health (CDRH) is
asked with assuring the safety, effectiveness, and quality
f medical devices, assuring the safety of radiation-
mitting products, fostering innovation, and providing
he public with accurate, science-based information about
he products we oversee, throughout the total product life
ycle (1). In order to enhance our ability to fulfill our
ission, CDRH developed a strategic plan to identify
riority areas for 2010. One of our goals is to proactively
elp facilitate medical device innovation and address
nmet public health needs (2). To accomplish this
bjective, CDRH believes it is critical to leverage our
egulatory authority and unique understanding of the
roducts we oversee, as well as to establish strong
orking relationships with our partners in the federal
overnment and external constituencies, and to advance
nnovative solutions to critical public health challenges (2).
One example of this type of collaboration is participa-
ion by members of CDRH’s Division of Cardiovascular
evices in the efforts of the Valve Academic Research
onsortium (VARC), an independent group that in-
ludes members of academic research organizations, car-
iovascular professional societies (clinical and interven-
ional cardiology and cardiothoracic surgery), and the
edical device industry. The Valve Academic Research
onsortium was established in response to the burgeon-
ng interest in transcatheter aortic valve implantation
TAVI) by the medical community. Transcatheter aortic
alve implantation represents a potential breakthrough
echnology, offering a less invasive catheter-based treat-
ent option for patients with severe aortic stenosis, some
f whom may not be candidates for open heart surgery.
lthough a less invasive option to open surgery has many
ttractive features, TAVI involves highly novel devices
rom the Office of Device Evaluation, Center for Devices and Radiological Health,
.S. Food and Drug Administration, Silver Spring, Maryland. Funding was provided
y Cardialysis BV on behalf of the Valve Academic Research Consortium. This work
epresents the professional opinion of the authors and is not an official document,
gency guidance or policy of the U.S. Government, the Department of Health and
uman Services, or the Food and Drug Administration, nor should any officialm
ndorsement be inferred. The article has been co-published in the European Heart Journal.
Manuscript received October 20, 2010; accepted October 22, 2010nd presents many complex challenges in the design,
onduct, and interpretation of clinical trials.
To address some of these challenges, VARC employed
multidisciplinary approach to develop consensus re-
arding standardized definitions for adverse events and
ecommendations for single and composite endpoints
hat reflect appropriate device-, procedure-, and patient-
elated safety and effectiveness measures for TAVI clin-
cal trials that enroll high-risk patients. This approach
esulted in a rigorous but clinically appropriate and
easonable set of recommendations. The FDA anticipates
ncorporating many of the recommendations put forth in
he consensus document into the TAVI clinical trials
eviewed and regulated by the Agency. As such, we
elieve that the VARC document can help improve the
fficiency with which TAVI clinical trials are designed
nd executed.
We continue to encourage sponsors to contact the
gency early in device development to begin discussions
egarding specific endpoints for studies intended to support
DA approval. While a common set of definitions and
ndpoints is very helpful, critical trial design elements may
epend on the particular device and patient population
eing studied. Also, many of the most difficult challenges
ssociated with these devices involve preclinical testing
ssues due to the anatomically and hemodynamically chal-
enging aortic environment where these devices must per-
orm well for long periods of time. Therefore, it is extremely
mportant that sponsors understand FDA’s preclinical test-
ng requirements as early as possible so that adequate fatigue
esting, finite element analysis modeling, and animal studies
an be completed for these innovative devices. It is our hope
hat publication of the VARC document will encourage
ponsors and investigators to make use of early interaction
ith the Agency. For this field to mature in the USA, it is
ssential that FDA, sponsors, and investigators continue to
ollaborate closely to develop high-quality clinical data that
ltimately results in benefits for patients.
The Food and Drug Administration also acknowledges the
mportance of the global approach adopted by VARC, both in
erms of geography (representatives from the scientific com-
unity in both USA and Europe) and expertise (surgeons,
nterventional cardiologists, clinical cardiologists, clinical trial-
sts, and other allied specialists), which we believe was instru-ental to the success of this initial undertaking. Such a process
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here are multiple areas of medicine in which this collegial and
omprehensive approach would be beneficial. Finally, the
onsensus report represents the first step in what promises to
e a dynamic process, and the Agency looks forward to
ontinued involvement with VARC as the technology and
linical application of TAVI evolves.
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